Kerry Mullaney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kerry Mullaney has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Marc Ladanyi
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
27 shared publications - Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
21 shared publications - Antoine Desilets
Hematology-Oncology Service, Department of Medicine, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC H2X 0A9, Canada
21 shared publications - Clare Wilhelm
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
21 shared publications - Eli Louis Diamond
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
21 shared publications - Ezra Rosen
Memorial Sloan Kettering Cancer Center 5 Evelyn H. Lauder Breast Center New York, New York
21 shared publications
Latest Publications
- 4 December 2024
- Published by Wiley in Histopathology
- Vol. 86 (5) , 728-741
Targeted RNA sequencing in diagnostically challenging head and neck carcinomas identifies novel MON2::STAT6, NFATC2::NUTM2B, POC5::RAF1, and NSD3::NCOA2 gene fusions
Aims: Although molecular tests developed for a growing list of oncogenic alterations have significantly aided in the classification of head and neck carcinomas, tumours in which prototypical histologic and immunophenotypic features are lacking or only partially developed continue to pose diagnostic challenges. Searching for known diagnostic and therapeutic targets by clinical next‐generation sequencing (NGS) assays can often lead to new discoveries.Methods and Results: We present our institutional experience in applying targeted RNA NGS in 36 head and neck carcinomas that were morphologically difficult to classify between 2016 and 2023. The patients ranged in age from 5 to 83 years (median, 64), with the majority of tumors occurring in the major salivary glands and the sinonasal tract. Overall, seven (19%) cases showed unusual gene rearrangements, including five novel alterations: MON2::STAT6 in a hard palate adenocarcinoma with mucinous features, POC5::RAF1 in apocrine intraductal carcinoma of the lacrimal gland, EWSR1::CDADC1 fusion in a basaloid carcinoma of the submandibular gland, NFATC2::NUTM2B in myoepithelial carcinoma, and NSD3::NCOA2 fusion in a peculiar high‐grade carcinoma with a peritheliomatous growth pattern, and focal myogenic differentiation. Potential therapeutic actionability was identified in three cases (RAF1 and FGFR2 fusions).Conclusion: These findings broaden the current spectrum of gene rearrangements in head and neck carcinomas and support the utility of clinical NGS in identifying unusual, actionable alterations in diagnostically challenging cases.
- 4 December 2024
- Published by Wiley in Histopathology
- Vol. 86 (5) , 728-741
Targeted RNA sequencing in diagnostically challenging head and neck carcinomas identifies novel MON2::STAT6, NFATC2::NUTM2B, POC5::RAF1, and NSD3::NCOA2 gene fusions
Aims: Although molecular tests developed for a growing list of oncogenic alterations have significantly aided in the classification of head and neck carcinomas, tumours in which prototypical histologic and immunophenotypic features are lacking or only partially developed continue to pose diagnostic challenges. Searching for known diagnostic and therapeutic targets by clinical next‐generation sequencing (NGS) assays can often lead to new discoveries.Methods and Results: We present our institutional experience in applying targeted RNA NGS in 36 head and neck carcinomas that were morphologically difficult to classify between 2016 and 2023. The patients ranged in age from 5 to 83 years (median, 64), with the majority of tumors occurring in the major salivary glands and the sinonasal tract. Overall, seven (19%) cases showed unusual gene rearrangements, including five novel alterations: MON2::STAT6 in a hard palate adenocarcinoma with mucinous features, POC5::RAF1 in apocrine intraductal carcinoma of the lacrimal gland, EWSR1::CDADC1 fusion in a basaloid carcinoma of the submandibular gland, NFATC2::NUTM2B in myoepithelial carcinoma, and NSD3::NCOA2 fusion in a peculiar high‐grade carcinoma with a peritheliomatous growth pattern, and focal myogenic differentiation. Potential therapeutic actionability was identified in three cases (RAF1 and FGFR2 fusions).Conclusion: These findings broaden the current spectrum of gene rearrangements in head and neck carcinomas and support the utility of clinical NGS in identifying unusual, actionable alterations in diagnostically challenging cases.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 4. Oncoprint for de novo BRAF fusions.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 4. Oncoprint for de novo BRAF fusions.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 4. Treatments prior to identification of acquired BRAF fusions.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 4. Treatments prior to identification of acquired BRAF fusions.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 4. Treatments prior to identification of acquired BRAF fusions.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 4. Treatments prior to identification of acquired BRAF fusions.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 1. Consort Diagram.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 1. Consort Diagram.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 3. Structures of top 13 most common BRAF fusion isoforms.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 3. Structures of top 13 most common BRAF fusion isoforms.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 1. Baseline characteristics of patients with de novo and acquired BRAF fusions.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Table 1. Baseline characteristics of patients with de novo and acquired BRAF fusions.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 4. Oncoprint for de novo BRAF fusions.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Supplemental Figure 4. Oncoprint for de novo BRAF fusions.